

Please type a plus sign (+) inside this box →



02-26-07

1648/22W  
Grey

PTO/SB/21 (06-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

<b>Application Number</b>	<b>10/568,301</b>		
	<b>Filing Date</b>	<b>January 26, 2007</b>	
	<b>First Named Inventor</b>	<b>Zeng, Fu-Yue</b>	
	<b>Group Art Unit</b>	<b>3381</b>	
	<b>Examiner Name</b>	<b>Unknown</b>	
<b>Total Number of Pages in This Submission</b>	<b>3</b>	<b>Attorney Docket Number</b>	<b>AREN-065</b>

### ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <b>Form PTO/SB/8A (1 pg)</b> <b>10 References</b> <b>Return postcard</b>
<b>Remarks</b>		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


<b>Signing Attorney/Agent (Reg. No.)</b>	<b>JAMES S. KEDDIE, PH.D., 48,920</b> <b>BOZICEVIC, FIELD &amp; FRANCIS, LLP</b>
<b>Signature</b>	
<b>Date</b>	<b>February 23, 2007</b>

**EXPRESS MAIL LABEL NO. EV 577 671 978 US**

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail No. EV 577 671 978 US

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>  Address to: Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	AREN-065
	First Named Inventor	Zeng, Fu-Yue
	Application Number	10/568,301
	Confirmation No.	3381
	Filing Date	January 26, 2007
	Group Art Unit	Unknown
	Examiner Name	Unknown
	Title: "METHODS AND COMPOSITIONS RELATING TO MODULATION OF GPCR SIGNALING"	

Sir:

This is a Supplemental Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.


This Supplemental Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. § 102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. AREN-065 may be charged thereon.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Date: February 23, 2007

By   
James S. Keddie, Ph.D.  
Registration No. 48,920

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Application Number	10/568,301
				Filing Date	January 26, 2007
				First Named Inventor	Fu-Yue Zeng
				Group Art Unit	3381
				Examiner Name	unknown
Sheet	1	of	1	Attorney Docket Number	AREN-0065

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1					
	A2					

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup> (if known)				
	B1						

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	SEXTON et al., "Receptor activity modifying proteins," Cellular Signalling (2001) 13:73-83	
	C2	RIOS et al., "G-protein-coupled receptor dimerization: modulation of receptor function," Pharmacology & Therapeutics (2001) 92:71-87	
	C3	ANGERS et al., "DIMERIZATION: An Emerging Concept for G Protein-Coupled Receptor Ontogeny and Function," Annual Review of Pharmacology and Toxicology (2002) 42:409-435	
	C4	ANGNATI et al., "Molecular Mechanisms and Therapeutic Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons," Pharmacological Reviews 92(003) 55:509-550	
	C5	JOOST et al., "Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands," Genome Biology (2002) 3(11)research0063.1-0063.16:1-16	
	C6	MCVEY et al., "Monitoring Receptor Oligomerization Using Time-resolved Fluorescence Resonance Energy Transfer and B Bioluminescence Resonance Energy Transfer," The Journal of Biological Chemistry (2001) 276-14092-14099	
	C7	HILAIRET et al., "Hypersensitization of the Orexin 1 Receptor by the CB1 Receptor," The Journal of Biological Chemistry (2003) 278-23731-23737	
	C8	XU et al., "Heterodimerization of $\alpha_2A$ - and $\beta_1$ - Adrenergic Receptors," The Journal of Biological Chemistry (2003) 278:10770-10777	
	C9	FLOYD et al., "C5a Receptor Oligomerization," The Journal of Biological Chemistry (2003) 278-35354-35361	
	C10	KLCO et al., "C5a Receptor Oligomerization," The Journal of Biological Chemistry (2003) 278:35345-35353	
	C11		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.